Open letter to executives of GTHP,
FDA approval is obviously what is needed and even if this device is an improved method of screening, approval is a costly process and squashing promising competition through bureaucratic means can be an added obstacle. If it is as promising as I thought it was when I started buying stock then it fading away will be a worse loss for those who will benefit from this technology than our financial setbacks.
Assuming it is as good as the reported data indicates ( 95+ % accuracy with quicker results and no biopsy) then some level of support should be forthcoming from reputable sources that would get the attention of investors and public health officials—- enough to rebound stock prices to a respectable level.
The FDA has been reported to be more open to fast tracking devices that benefit patients and bring down costs than it was under the previous administration.
Somewhere in this country there has To be some combination of one or more of a cancer clinic administrator, university research faculty member, public health official ( even at a state or local level), women’s health advocacy group, politician wanting to appear concerned about constituents( it is an election year). It is critical that finding and publicizing support from two or three such reputable individuals or organizations be the imediate priority of the executives of this company.
That is what will bring in investors, spur action by regulators and salvage this company ( if it actually worthy of it). Keep selling discounted notes and stock and waiting for the bureaucracy to work and this will fail, you don’t have the staying power. It needs more than a nudge, it needs a shove. Market the concept publicly with even tentative support from representatives of these groups and you may still succeed to the benefit of patients, stockholders and yourselves.
Stay on the current track and failure is sure.
